Pharmaceutical: The Last Six Months
Of Federal Activity

About

This Report

This is a computer-generated report that shows all of the federal activity with respect to the keyword "Pharmaceutical" over the last six months. This is a demonstration of the power of our government relations automation software.

Hansard

House: 32 Speeches
Senate: 10 Speeches

House Senate

Bills

Active: 0

Regulations

Filed: 4
Proposed: 0

Regulations

The House

Hon. Andrew Scheer (Leader of the Opposition, CPC)

December 12th
Hansard Link

Oral Questions

“...rting. It was the Liberals who agreed to a cap on auto exports. They agreed to adopt Donald Trump's pharmaceutical regime, increasing costs for Canadian patients. After giving all of that away to Dona...”

Ms. Tracey Ramsey (Essex, NDP)

December 12th
Hansard Link

Adjournment Proceedings

“...rt deal for big pharma. This is the Liberals letting Canadians know that they will stand up for big pharmaceutical companies and they will not stand up for Canadians.

Why did the Liberals agree ...”

Mr. Stéphane Lauzon (Parliamentary Secretary to the Minister of Veterans Affairs and Associate Minister of National Defence, Lib.)

December 12th
Hansard Link

Adjournment Proceedings

“...mple, our government is working closely with the provinces and territories through the pan-Canadian Pharmaceutical Alliance to lower drug costs.[Translation]

By capitalizing on the combined negotiating power of governments, the pan-Canadian Pharmaceutical Alliance carried out more than 207 joint negotiations on brand name drugs.

They obtained price reductions on more than 70 generic drugs. In 2017, it was estimated that the efforts of the pan-Canadian Pharmaceutical Alliance had led to nearly $1.3 billion in savings per year.[English]

Health Ca...”

Ms. Rachael Harder (Lethbridge, CPC)

December 4th
Hansard Link

Business of Supply

“...tion.

The government backed down on automotive, it backed down on dairy and it backed down on pharmaceuticals. As well, for all these concessions, Canada was unable to win anything significant i...”

Mr. Bill Casey (Cumberland—Colchester, Lib.)

November 26th
Hansard Link

Routine Proceedings

“...report of the Standing Committee on Health, entitled “Towards Open Science: Promoting Innovation in Pharmaceutical Research and Development and Access to Affordable Medications both in Canada and Abroad”. Pursuant to Standing Order 109, the committee requests that the government table a comprehensive response to this report. Basically, the report encourages funding investments in clinical research and innovation and also wants to ensure that the research results in lower costs for pharmaceuticals.

I want to thank all members of the committee, who worked hard on this, as wel...”

Mr. Kelly McCauley (Edmonton West, CPC)

November 7th
Hansard Link

Government Orders

“... in the Middle East. It is a world leader in technological innovation. We also see that it leads in pharmaceutical innovation.

Before a friend of mine unfortunately passed away from ALS, he was ...”

Hon. Andrew Scheer (Leader of the Opposition, CPC)

October 15th
Hansard Link

Oral Questions

“...actly what the government did. It capitulated on access to Canada's dairy market. It capitulated on pharmaceuticals, agreeing to Donald Trump's plan for higher drug costs for Canadians. It actually ag...”

Mr. Omar Alghabra (Parliamentary Secretary to the Minister of International Trade Diversification, Lib.)

October 5th
Hansard Link

Government Orders

“...such as aerospace, chemicals, cosmetics, industrial machinery, medical devices, metal and minerals, pharmaceuticals and plastics.

I have given just a snapshot of Canada's vibrant economy, and there are many more sectors in which exporters would benefit from the CPTPP. Securing preferential access to CPTPP markets would mean that almost all Canadian products could be exported to our CPTPP partners without facing tariffs. Upon full implementation of the agreement, 99% of tariff lines for CPTPP parties would become duty-free, covering 98% of Canada's current total exports to CPTPP markets.

The benefits of the CPTPP would not stop there. In addition to addressing traditional trade-policy issues, such as tariffs and technical barriers to trade, the CPTPP would cover trade in services, investment, intellectual property, government procurement and state-owned enterprises. These parts of the agreement would serve to provide Canadian companies, service providers and investors alike with transparency, predictability and certainty in their access to CPTPP markets.

For example, the national treatment and most-favoured-nation provisions, combined with a ratchet mechanism, would mean that Canadian service providers' and investors' access to CPTPP markets could only improve over time as they took steps toward greater liberalization, including when they completed free trade agreement negotiations with other countries around the world. This means that the CPTPP would not only open new markets for Canada today but that our access would improve in the future.

This would be complemented by the commitments made on government procurement in the CPTPP, which would establish fair, open and transparent rules for competitive procurement markets. Canadian businesses would enjoy equal treatment vis-à-vis domestic suppliers when bidding for government contracts in CPTPP markets. As a result, Canadian suppliers would benefit from new opportunities in markets such as Australia, Brunei, Malaysia and Vietnam while gaining expanded government procurement access with existing FTA partners, such as Chile and Peru. It is now clearer than ever that the CPTPP is a big deal for Canadian businesses and workers. (1010)

We are making good on our commitment to create opportunities for small and medium-sized enterprises and to generate economic growth that will benefit all Canadians. This agreement would tear down barriers and build a bridge across the Pacific for Canadian exporters of goods and services.

With the CPTPP, Canada would send a clear signal to the world that it stands firm in its support for a free, rules-based international trading system. In the wake of rising protectionist sentiments around the world, the ratification of the CPTPP would not just secure economic benefits for us today but would solidify our role in the economic architecture of Asia tomorrow and for decades to come. For these reasons, our government is committed to ratifying and bringing the CPTPP into force, and it is why I encourage hon. members of the House to support the bill before us today.

I want to also take a moment to relate the benefits of the CPTPP to my city, the great city of Mississauga. The city of Mississauga is host to 10% of the Fortune 500 companies in Canada. Ten per cent of Fortune 500 companies have their headquarters situated in Mississauga. Most, if not all, of these companies, including the aerospace industry, pharmaceuticals, food processors, engineering companies and financial institutions, would see tremen...”

Mr. Joël Godin (Portneuf—Jacques-Cartier, CPC)

October 5th
Hansard Link

Government Orders

“...e. That is quite something.

In addition, the agreement extends the data protection period for pharmaceuticals. That means that it will cost Canadians a lot more to stay healthy. That is an impre...”

Hon. Andrew Leslie (Parliamentary Secretary to the Minister of Foreign Affairs (Canada-U.S. Relations), Lib.)

October 5th
Hansard Link

Oral Questions

“...ovinces and territories to make prescription drugs more affordable. We have joined the pan-Canadian Pharmaceutical Alliance, which has helped Canadians save over $2 billion annually. We are investing ...”

Ms. Karine Trudel (Jonquière, NDP)

October 5th
Hansard Link

Government Orders

“...d that worries me greatly. The CPTPP will only make things worse. It makes even more concessions to pharmaceutical companies, which will increase Canadians' annual drug expenditures by more than $800 ...”

Ms. Kate Young (London West, Lib.)

October 4th
Hansard Link

Statements by Members

“...s old. This small business holds a special place in the hearts of many Londoners as it has provided pharmaceutical, vitamin and herbal remedies to the community for eight decades. Our government knows...”

Hon. Andrew Scheer (Leader of the Opposition, CPC)

October 3rd
Hansard Link

Oral Questions

“...ld Trump. Even after all of that, he still had to back down on so many key areas. He backed down on pharmaceuticals, meaning that Canadian patients and the provincial health care systems will have to ...”

Hon. Andrew Scheer (Leader of the Opposition, CPC)

October 3rd
Hansard Link

Oral Questions

“.... The Prime Minister has just backed down, by giving Donald Trump's policy preference over Canadian pharmaceuticals, meaning higher prices for patients.

In return for backing down on pharmaceuticals, on accepting a cap on autos, what has he got in return?

Yesterday, the Minist...”

Hon. Pierre Poilievre (Carleton, CPC)

October 3rd
Hansard Link

Oral Questions

“...My colleague asked when the steel tariffs will be removed. The Prime Minister has backed down on pharmaceuticals, dairy, and so much else. I ask again, when will the steel tariffs be removed? When?...”

Hon. Pierre Poilievre (Carleton, CPC)

October 3rd
Hansard Link

Oral Questions

“... Minister who was clearly floundering from the beginning. Now we have the result. He backed down on pharmaceuticals with higher drug prices for Canadian seniors. He backed down on dairy, imposing Cana...”

Ms. Elizabeth May (Saanich—Gulf Islands, GP)

October 3rd
Hansard Link

Government Orders

“...ed to enter our marketplace. We remain concerned about the USMCA giving longer patent protection to pharmaceutical companies, thus driving up drug costs. We remain concerned about other sectors that a...”

Mr. Omar Alghabra (Parliamentary Secretary to the Minister of International Trade Diversification, Lib.)

October 3rd
Hansard Link

Government Orders

“...trial machinery, medical devices, information and communications technologies, metals and minerals, pharmaceuticals and plastics.

The benefits of the CPTPP do not stop there.

The agreement...”

Mr. Ben Lobb (Huron—Bruce, CPC)

October 3rd
Hansard Link

Government Orders

“...the “M”.

There are buy America provisions, steel and aluminum tariffs, further IP protection, pharmaceuticals and concessions on supply management that it appears none of them are going to ever ...”

Hon. Andrew Scheer (Leader of the Opposition, CPC)

October 2nd
Hansard Link

Oral Questions

“...ome back with an improved deal. Now we know what the government has given up. It has backed down on pharmaceuticals, meaning Canadian patients will have to pay more so U.S. companies can make bigger p...”

Hon. Andrew Scheer (Leader of the Opposition, CPC)

October 2nd
Hansard Link

Oral Questions

“...ality, this is NAFTA 0.5. They have made so many concessions on key areas. They have backed down on pharmaceuticals. They have backed down on dairy. In fact, they gave away so much that Donald Trump's...”

Hon. Chrystia Freeland (Minister of Foreign Affairs, Lib.)

October 2nd
Hansard Link

Oral Questions

“...he provinces and territories to make prescription drugs more affordable. We joined the pan-Canadian Pharmaceutical Alliance, which has helped Canadians save over $2 billion annually. We are investing ...”

Mrs. Marilène Gill (Manicouagan, BQ)

October 1st
Hansard Link

Statements by Members

“...reater competitive advantage. Chalk up another loss for health care with Ottawa protecting American pharmaceutical companies from low-cost drugs.

Ottawa gave Mr. Trump everything he wanted and g...”

Hon. Andrew Scheer (Leader of the Opposition, CPC)

October 1st
Hansard Link

Oral Questions

“...as made concessions on dairy, he has made concessions on auto quotas and he has made concessions on pharmaceuticals, meaning that Canadian patients will have to pay higher drug costs. We would have ho...”

Hon. Andrew Scheer (Leader of the Opposition, CPC)

October 1st
Hansard Link

Oral Questions

“... on dairy. He has backed down to Donald Trump on auto quotas. He has backed down to Donald Trump on pharmaceuticals, meaning Canadian patients will have to pay higher drug costs.

After making al...”

Hon. Pierre Poilievre (Carleton, CPC)

October 1st
Hansard Link

Oral Questions

“...state and local projects south of the border, yet the government has backed down to Donald Trump on pharmaceuticals, with higher drug prices for Canadians; and has backed down on copyright, dairy and ...”

Hon. Pierre Poilievre (Carleton, CPC)

October 1st
Hansard Link

Oral Questions

“...the word “capitulate” because capitulate is precisely what they have done. They have capitulated on pharmaceuticals, allowing Trump to force higher drug costs on Canadian patients to boost American dr...”

Hon. Pierre Poilievre (Carleton, CPC)

October 1st
Hansard Link

Oral Questions

“...Canadian auto exports. They backed down to Donald Trump, forcing Canadians to pay higher prices for pharmaceuticals. We know they backed down on copyright, dairy and other policies. What did they get ...”

Ms. Linda Lapointe (Rivière-des-Mille-Îles, Lib.)

September 18th
Hansard Link

Government Orders

“...ve committed to eliminating restrictive red tape in sectors such as cosmetics, medical instruments, pharmaceuticals, and ICTs, and this will give Canadian manufacturing exporters greater certainty and...”

Mr. Peter Fonseca (Mississauga East—Cooksville, Lib.)

September 18th
Hansard Link

Government Orders

“... that burdensome and restrictive regulatory red tape in such sectors as cosmetics, medical devices, pharmaceuticals and ICT will provide Canadian manufacturing exporters with greater certainty and pre...”

Ms. Tracey Ramsey (Essex, NDP)

September 17th
Hansard Link

Government Orders

“...ght terms, minimum terms of data protections for biologics and rules that would have encouraged the pharmaceutical practice of evergreening. If the United States were to rejoin the pact, the suspended provisions could be be brought back to life with the consensus of treaty members. This is very dangerous. It could lead to more stringent patent terms and higher drug costs for Canadians. In fact, we are anxiously waiting to see right now if a revised NAFTA will contain some of these same or even worse proposals. Canadians are very worried about this. At a time when the government should be introducing universal pharmacare and not just studying it again, and working to lower the cost of Canadians' prescription medications, they could in fact be setting us up for the opposite.

Now I want to talk a little bit about the rebranding and about the “P” in the CPTPP that stands for progressive. How can the Liberals brand this deal as progressive? Let us talk about some of the issues that exist in that. The new mandate letter, I should point out, for the new International Trade Diversification Minister omits any reference to this Liberal so-called progressive agenda, which is quite telling I think.

The CPTPP has no chapters on gender or on the rights of indigenous people, which is something that the government said was important in the course of NAFTA negotiations. Why has it disappeared from the CPTPP? The CPTPP does not even mention the words “climate change” and its labour provisions are extremely weak. It contains provisions that will weaken Canada's supply-managed sector. It contains harmful ISDS provisions that have been destructive for environment and corrosive to the sovereignty of our government. None of those things are particularly progressive. I will give my colleagues a quote from Scott Sinclair at the Canadian Centre for Policy Alternatives. He stated:

If the Trudeau government’s rhetoric about progressive trade and inclusive growth means anything—which is an open question—then it requires a genuine rebalancing of trade treaties to better protect workers, citizens and the environment, and to confront the 21st century challenges of extreme inequality and runaway climate change. (1310)

The next thing I would like to discuss a little is the consultations. Certainly the Liberal government is in favour of consultations, although the meaningfulness of those consultations has really come under scrutiny, particularly over the NAFTA talks that happened over the summer.

As I have said, the Conservatives signed us on to this deal in 2015 during the campaign. As soon as the Liberals took office, they promised that their new government would be different and that it would consult with the public. Instead of undertaking meaningful public consultations, the government passed this on to the international trade committee, of which I am the vice-chair. Our trade committee's so-called public consultations were widely criticized for restricting public participation in a variety of ways. For example, we received over 8,000 submissions from Canadians, but we struggled to translate and adequately review all these submissions. The fact is that the committees, not just my own, have limited resources, and are not equipped to do true public consultations. The Liberals love to say that they are consulting, but their shallow definition of what constitutes public consultation is very troublesome. This was shown in the recent court ruling on the pipeline and the government's failure to properly consult indigenous people.

On the TPP, the trade committee hearings allowed for a one-hour time slot for the public to make presentations. Every city we toured was filled with people who wanted to speak about the TPP. In Montreal, 19 out of 19 public presenters were opposed. In Quebec City, three out of three were opposed. We heard from more than 400 witnesses and received written comments from more than 60,000 Canadians, of whom 95% were opposed to the TPP.

According to Global Affairs documents obtained by The Council of Canadians, only two out of 18,000 Canadians wrote to the government in support of the TPP. I want to repeat that: two out of 18,000 people who wrote the government expressed support. That means only .01% of everyone who participated in these email consultations supported the deal. It is no wonder the Liberals are using the guise of public consultations as cover to sign Canada on to the job-killing TPP.

Let us talk about the timing. At a time when the Trump administration is threatening to implement devastating auto tariffs, both the Conservatives and Liberals are championing a trade deal that would put 58,000 Canadian jobs at risk, 20,000 in auto parts alone. The leader of the Conservative Party asked to recall the House of Commons in the summer in order to ram through the TPP trade deal, which would decimate these industries, industries that are already endangered under Trump's outrageous tariffs. There could not be a worse time to be ratifying the CPTPP. Destroying one industry in hopes that another one will eventually grow is not diversification; it is a death sentence for our domestic sectors. Conservatives may be comfortable turning their backs on the auto sector, as it appears the Liberals are, but New Democrats will stand strong with them in these very difficult times.

Let us talk about tariffs. We know the CPTPP would lead to the elimination of tariffs on a range of imported goods and exports in sectors like aerospace, metals and minerals, chemicals and plastics, industrial machinery, pharmaceuticals, agriculture and agrifood, fish and seafood, and forestry and value-added wood produ...”

Mr. Omar Alghabra (Parliamentary Secretary to the Minister of International Trade Diversification, Lib.)

September 17th
Hansard Link

Government Orders

“..., like aerospace, chemicals, cosmetics, industrial machinery, medical devices, metals and minerals, pharmaceuticals and glasses. It will also provide benefits for consumers, with lower prices and more...”


The Senate

Senator Carignan

December 13th
Hansard Link

Health Genetic Non-Discrimination

“What role did pharmaceutical lobbies and insurance company lobbies play in the government’s decision to abandon the legislation? [English]”

Hon. Judith G. Seidman

December 12th
Hansard Link

Health Pharmaceutical Drugs

“...e senators, my question is for the Leader of the Government in the Senate and concerns shortages of pharmaceutical drugs. This fall there was a severe Canada-wide shortage of both the brand and generi...”

Hon. Bill Morneau, P.C., M.P., Minister of Finance

December 4th
Hansard Link

Ministry of Finance Pharmacare System

“...tasked an advisory committee with looking at the possible paths forward in dealing with gaps in the pharmaceutical delivery system in our country. That report has not yet been prepared. I have not, no...”

Hon. Judith G. Seidman

October 31st
Hansard Link

Health Vanessa’s Law

“...servative government in 2014. In July, a Federal Court judge ruled that Health Canada must disclose pharmaceutical clinical trial data to a researcher seeking its release. Information the department t...”

Hon. Leo Housakos

October 2nd
Hansard Link

Foreign Affairs and International Trade United States-Mexico-Canada Agreement

“...r. We allowed better protection for patent drugs all of a sudden, meaning fewer jobs in our generic pharmaceutical industry and higher prices for Canadian consumers, so we sold down the river the generic pharmaceutical industry. We created an important breach in the auto pact with quotas that we have ac...”

Hon. Yonah Martin (Deputy Leader of the Opposition)

October 2nd
Hansard Link

Foreign Affairs and International Trade United States-Mexico-Canada Agreement

“... Leader in the Senate and it concerns the new trilateral trade agreement. Under the agreement, many pharmaceuticals will have their patent protection extended from eight to 10 years. This means that Canadians who use these prescription drugs will have to pay more and wait longer for less expensive generic versions. Yesterday was National Seniors Day, and we know that many seniors across our country already struggle with the high cost of medication. The types of drugs made more expensive by the new trade agreement include those used to treat arthritis and other chronic inflammatory diseases. My question, leader, is this: What did Canada receive in exchange for the concessions on pharmaceuticals, and what does the government plan to do for our seniors, who will have to pay more ...”

Hon. Peter Harder (Government Representative in the Senate)

October 2nd
Hansard Link

Foreign Affairs and International Trade United States-Mexico-Canada Agreement

“...nd access to prescription drugs. Senators will know that the government has joined the pan-Canadian Pharmaceutical Alliance, which negotiates lower drug prices on behalf of public drug plans. To date, I’m informed this has led to $1.2 billion of annual savings for Canadians. (1600) The government is also investing more than $140 million to improve access to pharmaceuticals and support innovation within the health care system, and they are working with the ...”

Hon. Chantal Petitclerc

September 27th
Hansard Link

Voluntary Blood Donations Bill Bill to Amend—Second Reading—Debate Continued

“...rapies. As you can appreciate, plasma is invaluable to the hospital system and increasingly for the pharmaceutical industry. The reality is that today, the global plasma industry posts annual sales of more than $14 billion. According to Canadian Blood Services, the demand for plasma-derived pharmaceutical products increases by 10 per cent a year. It is the same thing in the United States, Europe, and Australia. [English] Thanks to voluntary donations of blood to Canadian Blood Services and Héma-Québec, the supply of plasma for transfusions in Canada is self-sustaining most of the time. However, these two public bodies, which offer no financial compensation, struggle to meet the demand for plasma used to create pharmaceutical products. According to Health Canada, only 17 per cent of our plasma needs are met by...”

Hon. Pamela Wallin

September 20th
Hansard Link

Government’s Legal Obligation to Protect and Maintain a Voluntary Blood System Inquiry—Debate Concluded

“...ened up access to blood collection to private companies and issued operating licences to a national pharmaceutical company, Canadian Plasma Resources, which is now the chief for-profit entity that col...”

Senator Ringuette

June 19th
Hansard Link

Cannabis Bill Motion in Amendment Negatived

“...o acquire medical marijuana with a prescription. Quite honestly, I wondered just how much of a hand pharmaceutical companies had in that. I read the excellent presentation that former minister Benoît ...”


Filed Regulations

Regulations Amending the Food and Drug Regulations (Mica): SOR/2018-248

November 23, 2018 SOR/2018-248
FOOD AND DRUGS ACT
Gazette Link

“...market.

The use of mica coated with titanium dioxide and/or iron oxides will also provide an additional means for patients to differentiate pharmaceutical products since these colourants provide a pearlescent or “shimmer” effect which can be distinguishable from other colours. Being able to clearly differentiate different pharmaceutical products by colour may help reduce medication errors. It may also be useful to thwart counterfeiting of products insofar as the effect ...”


Regulations Amending the Medical Devices Regulations (Importation): SOR/2018-225

October 30, 2018 SOR/2018-225
FOOD AND DRUGS ACT
Gazette Link

“...e agreement.

The CPTPP includes annexes to the Technical Barriers to Trade (TBT) chapter addressing specific challenges faced by exporters of pharmaceuticals, medical devices, information and communications technology, and cosmetics, among others. In particular, Chapter 8 – TBT, A...”


Cannabis Regulations: SOR/2018-144

27, 2018 June
FOOD AND DRUGS ACT CONTROLLED DRUGS AND SUBSTANCES ACT CANNABIS ACT
Gazette Link

“...or (ii) restoring, correcting or modifying organic functions in human beings.

It includes cannabis that is an active pharmaceutical ingredient as defined in subsection C.01A.001(1) of the Food and Drug Regulations or that is manufactured or sold for use in a cli...”

“...eir duties, such as pharmacy, medicine, dentistry, veterinary medicine, pharmacology, chemistry, biology, pharmacy technician, laboratory technician, pharmaceutical regulatory affairs or supply chain management or security, or (iii) hold a diploma, certificate or credential that is awarded ...”

“...n 174, 175 or 176 or subsection 178(1); (b) has, on more than one occasion, self-administered a prescription drug contrary to accepted pharmaceutical practice; (c) has, on more than one occasion, distributed or administered a prescription drug to their spouse, common-law partner, parent or child, including a child adopted in fact, contrary to accepted pharmaceutical practice; or (d) is unable to account for the quantity of prescription drugs for which the pharmacist was responsible under this P...”

“... distributed or sold a cannabis product to their spouse, common-law partner, parent or child, including a child adopted in fact, contrary to accepted pharmaceutical practice; or (c) is unable to account for a quantity of cannabis products for which they were responsible under this Part, the Nar...”

“... (c) is manufactured, sold or represented for use in disinfection in premises in which food is manufactured, prepared or kept; (d) is an active pharmaceutical ingredient as defined in subsection C.01A.001(1) of the Food and Drug Regulations; (e) is a food or a cosmetic that does not ...”

“...oduct destined for retail sale.

Drugs containing cannabis Licensing

Drugs that contain cannabis, including cannabis that is an active pharmaceutical ingredient, will be regulated under both the Cannabis Act and the FDA, in much the same fashion as they are currently subject to both t...”

“...other cannabis products under the Cannabis Act and the Cannabis Regulations will not apply to drugs containing cannabis or cannabis that is an active pharmaceutical ingredient as defined under the FDR. For example, good production practices under the Cannabis Regulations would not apply because drug...”

“...ive good manufacturing practices.

While a drug establishment licence is required to fabricate, package and label, test and import an active pharmaceutical ingredient, wholesaling and distribution of active pharmaceutical ingredients are not licensable activities under the FDR. Therefore, those regulated parties will not be eligible for a cannabis drug li...”

“...eed derivatives that are compliant with the Industrial Hemp Regulations. Cannabis will also continue to be regulated under the FDA if it is an active pharmaceutical ingredient, a drug authorized for clinical trials, or a disinfectant. Also, food and cosmetics containing cannabis will not be exempt f...”


Regulations Amending the Use of Patented Products for International Humanitarian Purposes Regulations (Miscellaneous Program): SOR/2018-141

2018 June 25,
PATENT ACT
Gazette Link

“...e purpose of paragraph (b) of the definition average price in subsection 21.17(6) of the Act, the publications reporting the prices in Canada of pharmaceutical products sold by or with the consent of the patentee that are equivalent to the pharmaceutical product to which an authorization under section 21.04 of the Act relates are the following:

(a) the Ontario Drug Bene...”

“...h 3(a) of Form 10 of the schedule to the English version of the Regulations is replaced by the following:

(a) the quantities of the pharmaceutical product that were authorized under authorization number ________ to be manufactured and sold for export under section 21.04 of the...”

“...eloping and least-developed countries’ access to lower-cost medicines. The implementing legislation amended the Patent Act to enable a Canadian pharmaceutical manufacturer to apply to the Commissioner of Patents for a compulsory licence to export a lower cost, generic version of a patented pharmaceutical product to a developing or least-developed country unable to manufacture its own.

Both the August 30, 2003, decision and...”


Was This Useful? Try Our Real-Time Alerts Product: Free Trial

Operated by Global-Regulation Inc.